Citigroup initiated coverage on Karuna Therapeutics with a new price target
$KRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of Karuna Therapeutics with a rating of Buy and set a new price target of $291.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2023 | $291.00 | Buy | Citigroup |
| 12/12/2023 | $227.00 | Buy | Deutsche Bank |
| 8/22/2023 | $225.00 | Overweight | Wells Fargo |
| 7/20/2023 | $280.00 | Overweight | Morgan Stanley |
| 3/8/2023 | $214.00 | Neutral | Cantor Fitzgerald |
| 1/27/2023 | $209.00 | Neutral | UBS |
| 1/5/2023 | $285.00 | Overweight | Piper Sandler |
| 11/1/2022 | $288.00 | Buy | Loop Capital |